Compare Crocs, Inc. (CROX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Crocs (CROX) trades at $116.84, down 2.81% today, amid bearish technical signals but strong fundamental valuation metrics. The stock shows attractive P/E of 10.23 and P/S of 1.46, with robust profitability margins including 57.47% gross margin and 42.3% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.55 surpassing the $4.35 estimate. The company maintains strong cash flow generation despite a net loss in 2025, with management focusing on product innovation and HEYDUDE brand repositioning.

CROX presents a compelling value opportunity with discounted valuation multiples relative to historical performance, though near-term technical weakness and competitive pressures warrant caution. Analyst consensus remains bullish with $136.78 price target representing 17% upside potential. Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification initiatives. The stock's current levels offer entry points for long-term investors seeking exposure to a profitable footwear company with strong brand recognition.

DENTSPLY SIRONA (XRAY) trades at $8.69, near its 52-week low, with bearish technical signals and declining revenue trends. The company reported Q2 2026 earnings beat but faces margin pressure and negative profitability metrics. Recent news highlights institutional stake increases and ongoing restructuring efforts amid challenging dental market conditions.

The stock presents a high-risk opportunity with analyst consensus target of $13.40 suggesting 54% upside potential. However, persistent net losses, declining revenue, and bearish technical indicators warrant caution. Recovery depends on successful execution of turnaround initiatives and market share stabilization in competitive dental equipment sector.